Lastly, most patients in the AD group had biomarker confirmation of both significant Aβ and tau burden, and quantification of pathology burden based on PET suggested that the AD group had more severe AD pathology than the Aβ[ +] patients with RHI/TES. The gene discussed is MAPT; the disease is Alzheimer disease.